Jun 2026 (Q2 FY26) — Aug 13, 2026
Capricor Therapeutics Q2 FY26 — Deramiocel BLA Amendment and PDUFA Extension Planned
Read the full callCapricor Therapeutics (CAPR) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Capricor Therapeutics earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -40.7 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$6.65 −0.89% · −$0.06
Performance +6.4% 1Y
1Y: $6.25 on 17 Oct 2025 → $6.65. High $35.34 (21 Apr 2026), low $3.85 (31 Jul 2026).
- Previous close
- $6.71
- 52-week range
- $3.85 – $35.34
- One year
- +3.91%
Overview
- Symbol
- CAPR
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Capricor Therapeutics earnings calls (CAPR)
Financials
What the filings say
Net profit, year on year: −57% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2 | 11 | — | — | — | — | — | — |
| Operating profit | -13 | -8 | -25 | -28 | -26 | -29 | -37 | -43 |
| Operating margin | −575.2% | −69.2% | — | — | — | — | — | — |
| Other income | 0 | 1 | 1 | 2 | 2 | -1 | 3 | 2 |
| Profit before tax | — | — | -24 | -26 | — | — | -34 | -41 |
| Tax rate | — | — | 0.0% | −0.0% | — | — | 0.0% | 0.0% |
| Net profit | -13 | -7 | -24 | -26 | -25 | -30 | -34 | -41 |
| EPS ($ per share) | -0.38 | — | -0.53 | -0.57 | -0.54 | — | -0.59 | -0.70 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -67 | -74 | -88 | -108 | -137 | -159 | -200 | -305 |
| Total liabilities | 5 | 4 | 6 | 10 | 38 | 36 | 25 | 50 |
| Fixed assets | 1 | 0 | 1 | 2 | 5 | 6 | 6 | 18 |
| Investments | 3 | 6 | — | 0 | 32 | 25 | 140 | — |
| Total assets | 9 | 11 | 35 | 41 | 50 | 59 | 170 | 356 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -14 | -7 | -10 | -17 | 5 | -26 | -40 | -70 |
| Cash from investing | 5 | -3 | 5 | -1 | -35 | 5 | -116 | 97 |
| Cash from financing | 7 | 9 | 33 | 20 | 5 | 26 | 153 | 249 |
| Capital expenditure | -0 | 0 | -1 | -1 | -2 | -1 | -1 | -3 |
| Free cash flow | -14 | -7 | -11 | -18 | 3 | -27 | -41 | -73 |
Insider filings
32 filings between Dec 19, 2025 and Jun 25, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$8.37M
13 sales by 3 insiders
54% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 19
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Sabar Karimah Es | — | $3.76M | Apr 2, 2026 |
| Bergmann Anthony | — | $2.30M | Jun 25, 2026 |
| Krasney Karen | — | $2.30M | Jun 25, 2026 |
Latest filings (43)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 25, 2026 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Sale | 24,100 | $732.2K |
| Jun 25, 2026 | Krasney Karen EVP, GENERAL COUNSEL | Option exercise | 24,100 | $76.6K |
| Jun 25, 2026 | Krasney Karen EVP, GENERAL COUNSEL | Sale | 24,100 | $732.2K |
| Jun 25, 2026 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Option exercise | 24,100 | $76.6K |
| Jun 24, 2026 | Krasney Karen EVP, GENERAL COUNSEL | Option exercise | 400 | $1.3K |
| Jun 24, 2026 | Krasney Karen EVP, GENERAL COUNSEL | Sale | 400 | $12.0K |
| Jun 24, 2026 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Option exercise | 400 | $1.3K |
| Jun 24, 2026 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Sale | 400 | $12.0K |
| Jun 22, 2026 | Krasney Karen EVP, GENERAL COUNSEL | Option exercise | 500 | $1.6K |
| Jun 22, 2026 | Krasney Karen EVP, GENERAL COUNSEL | Sale | 500 | $15.0K |
| Jun 22, 2026 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Option exercise | 500 | $1.6K |
| Jun 22, 2026 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Sale | 500 | $15.0K |
| May 18, 2026 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Option exercise | 3,000 | $4.2K |
| May 13, 2026 | Litvack Frank Director | Option exercise | 3,937 | $5.5K |
| May 1, 2026 | Krasney Karen EVP, GENERAL COUNSEL | Option exercise 10b5-1 plan | 25,000 | $79.5K |
| May 1, 2026 | Krasney Karen EVP, GENERAL COUNSEL | Sale 10b5-1 plan | 25,000 | $792.5K |
| May 1, 2026 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 plan | 25,000 | $79.5K |
| May 1, 2026 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 25,000 | $792.5K |
| Apr 2, 2026 | Sabar Karimah Es Director | Option exercise 10b5-1 plan | 7,529 | $23.9K |
| Apr 2, 2026 | Sabar Karimah Es Director | Sale 10b5-1 plan | 7,529 | $240.9K |
| Apr 1, 2026 | Sabar Karimah Es Director | Sale 10b5-1 plan | 53,735 | $1.67M |
| Apr 1, 2026 | Sabar Karimah Es Director | Option exercise 10b5-1 plan | 53,735 | $261.2K |
| Mar 31, 2026 | Sabar Karimah Es Director | Option exercise 10b5-1 plan | 61,265 | $297.7K |
| Mar 31, 2026 | Krasney Karen EVP, GENERAL COUNSEL | Option exercise 10b5-1 plan | 693 | $963 |
| Mar 31, 2026 | Krasney Karen EVP, GENERAL COUNSEL | Option exercise 10b5-1 plan | 21,488 | $80.4K |
| Mar 31, 2026 | Krasney Karen EVP, GENERAL COUNSEL | Option exercise 10b5-1 plan | 2,819 | $9.0K |
| Mar 31, 2026 | Krasney Karen EVP, GENERAL COUNSEL | Sale 10b5-1 plan | 25,000 | $752.9K |
| Mar 31, 2026 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 plan | 25,000 | $79.5K |
| Mar 31, 2026 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 25,000 | $753.2K |
| Mar 31, 2026 | Sabar Karimah Es Director | Sale 10b5-1 plan | 61,265 | $1.85M |
| Dec 30, 2025 | Krasney Karen EVP, GENERAL COUNSEL | Option exercise | 2,500 | $3.5K |
| Dec 19, 2025 | DUNBAR GEORGE W JR Director | Option exercise | 3,000 | $4.2K |
| Mar 5, 2025 | Marban Linda CHIEF EXECUTIVE OFFICER | Other | 12,500 | $0 |
| Mar 3, 2025 | Marban Linda CHIEF EXECUTIVE OFFICER | Option exercise | 25,000 | $34.8K |
| Mar 3, 2025 | Litvack Frank Director | Option exercise | 25,000 | $34.8K |
| Mar 3, 2025 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Option exercise | 2,500 | $3.5K |
| Mar 3, 2025 | DUNBAR GEORGE W JR Director | Option exercise | 750 | $1.0K |
| Mar 3, 2025 | Litvack Frank Director | Tax withheld | 2,543 | $34.8K |
| Feb 27, 2025 | COLLIER EARL M JR Director | Option exercise | 750 | $1.0K |
| Jan 2, 2025 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Award | 3,342 | $0 |
| Dec 13, 2024 | Krasney Karen EVP, GENERAL COUNSEL | Option exercise | 8,000 | $11.1K |
| Dec 3, 2024 | Litvack Frank Director | Option exercise | 20,391 | $22.4K |
| Sep 20, 2024 | Nippon Shinyaku Co Ltd 10% owner | Purchase | 2,798,507 | $15.00M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for CAPRICOR THERAPEUTICS, INC.
Free account. Everything above stays public.
Write why you follow CAPRICOR THERAPEUTICS, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading